{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:49:21Z","timestamp":1793260161054,"version":"4.5.0"},"reference-count":66,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2020,6,17]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Scopolamine as a drug is often used to treat motion sickness. Derivatives of scopolamine\nhave also found applications as antispasmodic drugs among others. In neuroscience-related research, it\nis often used to induce cognitive disorders in experimental models as it readily permeates the bloodbrain\nbarrier. In the context of Alzheimer\u2019s disease, its effects include causing cholinergic dysfunction\nand increasing amyloid-\u03b2 deposition, both of which are hallmarks of the disease. Hence, the application\nof scopolamine in Alzheimer\u2019s disease research is proven pivotal but seldom discussed. In this review,\nthe relationship between scopolamine and Alzheimer\u2019s disease will be delineated through an\noverall effect of scopolamine administration and its specific mechanisms of action, discussing mainly\nits influences on cholinergic function and amyloid cascade. The validity of scopolamine as a model of\ncognitive impairment or neurotoxin model will also be discussed in terms of advantages and limitations\nwith future insights.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1871527319666200214104331","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T08:26:06Z","timestamp":1581668766000},"page":"85-93","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":126,"title":["Scopolamine, a Toxin-Induced Experimental Model, Used for Research in Alzheimer\u2019s Disease"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5060-0245","authenticated-orcid":true,"given":"Win Ning","family":"Chen","sequence":"first","affiliation":[{"name":"School of Science, Monash University Malaysia, 47500 Bandar Sunway, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0433-5070","authenticated-orcid":true,"given":"Keng Yoon","family":"Yeong","sequence":"additional","affiliation":[{"name":"School of Science, Monash University Malaysia, 47500 Bandar Sunway, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24040796","volume":"24","author":"Kohnen-Johannsen K.L.","year":"2019","unstructured":"Kohnen-Johannsen K.L.; Kayser O.; Tropane alkaloids: chemistry, pharmacology, biosynthesis and production. Molecules 2019,24(4)","journal-title":"Molecules"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00404160","volume":"7","author":"Aparkes M.W.","year":"1965","unstructured":"Aparkes M.W.; An examination of central actions characteristic of scopolamine: comparison of central and peripheral activity in scopolamine, atropine and some synthetic basic esters. Psychopharmacology (Berl) 1965,7(1),1-19","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jpainsymman.2008.07.007","volume":"38","author":"Wildiers H.","year":"2009","unstructured":"Wildiers H.; Dhaenekint C.; Demeulenaere P.; Clement P.M.; Desmet M.; Van Nuffelen R.; Gielen J.; Van Droogenbroeck E.; Geurs F.; Lobelle J.P.; Menten J.; Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care. J Pain Symptom Manage 2009,38(1),124-133","journal-title":"J Pain Symptom Manage"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1007\/s00520-013-1846-z","volume":"21","author":"Imai K.","year":"2013","unstructured":"Imai K.; Ikenaga M.; Kodama T.; Kanemura S.; Tamura K.; Morita T.; Sublingually administered scopolamine for nausea in terminally ill cancer patients. Support Care Cancer 2013,21(10),2777-2781","journal-title":"Support Care Cancer"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fphar.2014.00055","volume":"5","author":"Antor M.A.","year":"2014","unstructured":"Antor M.A.; Uribe A.A.; Erminy-Falcon N.; Werner J.G.; Candiotti K.A.; Pergolizzi J.V.; Bergese S.D.; The effect of transdermal scopolamine for the prevention of postoperative nausea and vomiting. Front Pharmacol 2014,5,55","journal-title":"Front Pharmacol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.nbd.2015.06.012","volume":"82","author":"Navarria A.","year":"2015","unstructured":"Navarria A.; Wohleb E.S.; Voleti B.; Ota K.T.; Dutheil S.; Lepack A.E.; Dwyer J.M.; Fuchikami M.; Becker A.; Drago F.; Duman R.S.; Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors. Neurobiol Dis 2015,82,254-261","journal-title":"Neurobiol Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.2174\/1871527316666170309142646","volume":"16","author":"Martin A.E.","year":"2017","unstructured":"Martin A.E.; Schober D.A.; Nikolayev A.; Tolstikov V.V.; Anderson W.H.; Higgs R.E.; Kuo M.S.; Laksmanan A.; Catlow J.T.; Li X.; Felder C.C.; Witkin J.M.; Further evaluation of mechanisms associated with the antidepressantlike signature of scopolamine in mice. CNS Neurol Disord Drug Targets 2017,16(4),492-500","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1111\/j.1365-2036.2006.02818.x","volume":"23","author":"Mueller-Lissner S.","year":"2006","unstructured":"Mueller-Lissner S.; Tytgat G.N.; Paulo L.G.; Quigley E.M.; Bubeck J.; Peil H.; Schaefer E.; Placebo- and paracetamol-controlled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain. Aliment Pharmacol Ther 2006,23(12),1741-1748","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2165\/00003495-200767090-00007","volume":"67","author":"Tytgat G.N.","year":"2007","unstructured":"Tytgat G.N.; Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs 2007,67(9),1343-1357","journal-title":"Drugs"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/bcp.13031","volume":"82","author":"Alvarez-Jimenez R.","year":"2016","unstructured":"Alvarez-Jimenez R.; Groeneveld G.J.; van Gerven J.M.; Goulooze S.C.; Baakman A.C.; Hay J.L.; Stevens J.; Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects. Br J Clin Pharmacol 2016,82(4),1011-1021","journal-title":"Br J Clin Pharmacol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2174\/1389203720666191107094949","volume":"21","author":"Ha Z.Y.","year":"2020","unstructured":"Ha Z.Y.; Mathew S.; Yeong K.Y.; Butyrylcholinesterase: a multifaceted pharmacological target and tool. Curr Protein Pept Sci 2020,21(1),99-109","journal-title":"Curr Protein Pept Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/npp.2011.199","volume":"37","author":"Jones C.K.","year":"2012","unstructured":"Jones C.K.; Byun N.; Bubser M.; Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 2012,37(1),16-42","journal-title":"Neuropsychopharmacology"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1001\/archneur.1974.00490320001001","volume":"30","author":"Drachman D.A.","year":"1974","unstructured":"Drachman D.A.; Leavitt J.; Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974,30(2),113-121","journal-title":"Arch Neurol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/BF02190112","volume":"14","author":"Berger B.D.","year":"1969","unstructured":"Berger B.D.; Stein L.; An analysis of the learning deficits produced by scopolamine. Psychopharmacology (Berl) 1969,14(4),271-283","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"9748","DOI":"10.1038\/srep09748","volume":"5","author":"Bajo R.","year":"2015","unstructured":"Bajo R.; Pusil S.; L\u00f3pez M.E.; Canuet L.; Pereda E.; Osipova D.; Maest\u00fa F.; Pekkonen E.; Scopolamine effects on functional brain connectivity: a pharmacological model of Alzheimer\u2019s disease. Sci Rep 2015,5,9748","journal-title":"Sci Rep"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00426592","volume":"52","author":"Ghoneim M.M.","year":"1977","unstructured":"Ghoneim M.M.; Mewaldt S.P.; Studies on human memory: the interactions of diazepam, scopolamine, and physostigmine. Psychopharmacology (Berl) 1977,52(1),1-6","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jalz.2005.09.004","volume":"1","author":"Snyder P.J.","year":"2005","unstructured":"Snyder P.J.; Bednar M.M.; Cromer J.R.; Maruff P.; Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. Alzheimers Dement 2005,1(2),126-135","journal-title":"Alzheimers Dement"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.neuroscience.2016.05.012","volume":"329","author":"Manuel I.","year":"2016","unstructured":"Manuel I.; Lombardero L.; LaFerla F.M.; Gim\u00e9nez-Llort L.; Rodr\u00edguez-Puertas R.; Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer\u2019s disease. Neuroscience 2016,329,284-293","journal-title":"Neuroscience"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1037\/0735-7044.118.1.223","volume":"118","author":"Atri A.","year":"2004","unstructured":"Atri A.; Sherman S.; Norman K.A.; Kirchhoff B.A.; Nicolas M.M.; Greicius M.D.; Cramer S.C.; Breiter H.C.; Hasselmo M.E.; Stern C.E.; Blockade of central cholinergic receptors impairs new learning and increases proactive interference in a word paired-associate memory task. Behav Neurosci 2004,118(1),223-236","journal-title":"Behav Neurosci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neulet.2014.11.027","volume":"585","author":"Hasanein P.","year":"2015","unstructured":"Hasanein P.; Mahtaj A.K.; Ameliorative effect of rosmarinic acid on scopolamine-induced memory impairment in rats. Neurosci Lett 2015,585,23-27","journal-title":"Neurosci Lett"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0079-6123(03)45015-2","volume":"145","author":"Hasselmo M.E.","year":"2004","unstructured":"Hasselmo M.E.; McGaughy J.; High acetylcholine levels set circuit dynamics for attention and encoding and low acetylcholine levels set dynamics for consolidation. Prog Brain Res 2004,145,207-231","journal-title":"Prog Brain Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/BF02245886","volume":"109","author":"Blokland A.","year":"1992","unstructured":"Blokland A.; Honig W.; Raaijmakers W.G.; Effects of intra-hippocampal scopolamine injections in a repeated spatial acquisition task in the rat. Psychopharmacology (Berl) 1992,109(3),373-376","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.neuroscience.2004.03.058","volume":"126","author":"Elvander E.","year":"2004","unstructured":"Elvander E.; Sch\u00f6tt P.A.; Sandin J.; Bjelke B.; Kehr J.; Yoshitake T.; Ogren S.O.; Intraseptal muscarinic ligands and galanin: influence on hippocampal acetylcholine and cognition. Neuroscience 2004,126(3),541-557","journal-title":"Neuroscience"},{"key":"ref=24","first-page":"357","volume":"13","author":"Peng X.Q.","year":"1992","unstructured":"Peng X.Q.; Ke J.; [Effects of 3 henbane drugs on acute forebrain ischemia and reperfusion injury in rats]. Zhongguo Yao Li Xue Bao 1992,13(4),357-358","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/jnc.13843","volume":"139","author":"Muramatsu I.","year":"2016","unstructured":"Muramatsu I.; Yoshiki H.; Uwada J.; Masuoka T.; Sada K.; Taniguchi T.; Nishio M.; Pharmacological evidence of specific acetylcholine transport in rat cerebral cortex and other brain regions. J Neurochem 2016,139(4),566-575","journal-title":"J Neurochem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0091-3057(89)90438-3","volume":"33","author":"Toide K.","year":"1989","unstructured":"Toide K.; Effects of scopolamine on extracellular acetylcholine and choline levels and on spontaneous motor activity in freely moving rats measured by brain dialysis. Pharmacol Biochem Behav 1989,33(1),109-113","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0006-8993(77)90995-7","volume":"128","author":"Szerb J.C.","year":"1977","unstructured":"Szerb J.C.; Hadh\u00e1zy P.; Dudar J.D.; Release of [3H]acetylcholine from rat hippocampal slices: effect of septal lesion and of graded concentrations of muscarnic agonists and antagonists. Brain Res 1977,128(2),285-291","journal-title":"Brain Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1748-1716.1980.tb06543.x","volume":"108","author":"Nordstr\u00f6m O.","year":"1980","unstructured":"Nordstr\u00f6m O.; Bartfai T.; Muscarinic autoreceptor regulates acetylcholine release in rat hippocampus: in vitro evidence. Acta Physiol Scand 1980,108(4),347-353","journal-title":"Acta Physiol Scand"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF01277959","volume":"97","author":"Pfister M.","year":"1994","unstructured":"Pfister M.; Boix F.; Huston J.P.; Schwarting R.K.; Different effects of scopolamine on extracellular acetylcholine levels in neostriatum and nucleus accumbens measured in vivo: possible interaction with aversive stimulation. J Neural Transm (Vienna) 1994,97(1),13-25","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.bbr.2009.06.012","volume":"204","author":"Riedel G.","year":"2009","unstructured":"Riedel G.; Kang S.H.; Choi D.Y.; Platt B.; Scopolamine-induced deficits in social memory in mice: reversal by donepezil. Behav Brain Res 2009,204(1),217-225","journal-title":"Behav Brain Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0022-510X(77)90073-9","volume":"34","author":"Perry E.K.","year":"1977","unstructured":"Perry E.K.; Gibson P.H.; Blessed G.; Perry R.H.; Tomlinson B.E.; Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 1977,34(2),247-265","journal-title":"J Neurol Sci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijdevneu.2013.12.006","volume":"33","author":"Gutierres J.M.","year":"2014","unstructured":"Gutierres J.M.; Carvalho F.B.; Schetinger M.R.; Agostinho P.; Marisco P.C.; Vieira J.M.; Rosa M.M.; Bohnert C.; Rubin M.A.; Morsch V.M.; Spanevello R.; Mazzanti C.M.; Neuroprotective effect of anthocyanins on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia in rats. Int J Dev Neurosci 2014,33,88-97","journal-title":"Int J Dev Neurosci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.neurobiolaging.2004.07.015","volume":"26","author":"Mohapel P.","year":"2005","unstructured":"Mohapel P.; Leanza G.; Kokaia M.; Lindvall O.; Forebrain acetylcholine regulates adult hippocampal neurogenesis and learning. Neurobiol Aging 2005,26(6),939-946","journal-title":"Neurobiol Aging"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.niox.2014.08.009","volume":"43","author":"Ray R.S.","year":"2014","unstructured":"Ray R.S.; Rai S.; Katyal A.; Cholinergic receptor blockade by scopolamine and mecamylamine exacerbates global cerebral ischemia induced memory dysfunction in C57BL\/6J mice. Nitric Oxide 2014,43,62-73","journal-title":"Nitric Oxide"},{"key":"ref=35","first-page":"737","volume":"14","author":"Hulme E.C.","year":"1978","unstructured":"Hulme E.C.; Birdsall N.J.; Burgen A.S.; Mehta P.; The binding of antagonists to brain muscarinic receptors. Mol Pharmacol 1978,14(5),737-750","journal-title":"Mol Pharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1523\/JNEUROSCI.05-06-01577.1985","volume":"5","author":"Kellar K.J.","year":"1985","unstructured":"Kellar K.J.; Martino A.M.; Hall D.P.; Schwartz R.D.; Taylor R.L.; High-affinity binding of [3H]acetylcholine to muscarinic cholinergic receptors. J Neurosci 1985,5(6),1577-1582","journal-title":"J Neurosci"},{"key":"ref=37","first-page":"493","volume":"50","author":"Schmeller T.","year":"1995","unstructured":"Schmeller T.; Sporer F.; Sauerwein M.; Wink M.; Binding of tropane alkaloids to nicotinic and muscarinic acetylcholine receptors. Pharmazie 1995,50(7),493-495","journal-title":"Pharmazie"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0163-7258(93)90027-B","volume":"58","author":"Caulfield M.P.","year":"1993","unstructured":"Caulfield M.P.; Muscarinic receptors--characterization, coupling and function. Pharmacol Ther 1993,58(3),319-379","journal-title":"Pharmacol Ther"},{"key":"ref=39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032082","volume":"7","author":"Falsafi S.K.","year":"2012","unstructured":"Falsafi S.K.; Deli A.; H\u00f6ger H.; Pollak A.; Lubec G.; Scopolamine administration modulates muscarinic, nicotinic and NMDA receptor systems. PLoS One 2012,7(2)","journal-title":"PLoS One"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/syn.20957","volume":"65","author":"Seeman P.","year":"2011","unstructured":"Seeman P.; Seeman N.; Alzheimer\u2019s disease: \u03b2-amyloid plaque formation in human brain. Synapse 2011,65(12),1289-1297","journal-title":"Synapse"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"6460","DOI":"10.1073\/pnas.95.11.6460","volume":"95","author":"Simons M.","year":"1998","unstructured":"Simons M.; Keller P.; De Strooper B.; Beyreuther K.; Dotti C.G.; Simons K.; Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998,95(11),6460-6464","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2174\/1871527318666191011145941","volume":"18","author":"Ahmad S.S.","year":"2019","unstructured":"Ahmad S.S.; Khan S.; Kamal M.A.; Wasi U.; The structure and function of alpha, beta and gamma-Secretase as therapeutic target enzymes into the development of Alzheimer\u2019s disease: a review. CNS Neurol Disord Drug Targets 2019,18(9),657-667","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2174\/1871527317666180627122448","volume":"17","author":"Singh A.","year":"2018","unstructured":"Singh A.; Hasan A.; Tiwari S.; Pandey L.M.; Therapeutic advancement in Alzheimer disease: new hopes on the horizon? CNS Neurol Disord Drug Targets 2018,17(8),571-589","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ijdevneu.2005.11.010","volume":"24","author":"Liskowsky W.","year":"2006","unstructured":"Liskowsky W.; Schliebs R.; Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein. Int J Dev Neurosci 2006,24(2-3),149-156","journal-title":"Int J Dev Neurosci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"593","DOI":"10.4103\/0253-7613.100383","volume":"44","author":"Bihaqi S.W.","year":"2012","unstructured":"Bihaqi S.W.; Singh A.P.; Tiwari M.; Supplementation of Convolvulus pluricaulis attenuates scopolamine-induced increased tau and amyloid precursor protein (A\u03b2PP) expression in rat brain. Indian J Pharmacol 2012,44(5),593-598","journal-title":"Indian J Pharmacol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/45159","volume":"402","author":"Patrick G.N.","year":"1999","unstructured":"Patrick G.N.; Zukerberg L.; Nikolic M.; de la Monte S.; Dikkes P.; Tsai L.H.; Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999,402(6762),615-622","journal-title":"Nature"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4103\/ijp.IJP_417_17","volume":"50","author":"Saikia B.","year":"2018","unstructured":"Saikia B.; Barua C.C.; Sarma J.; Haloi P.; Tamuli S.M.; Kalita D.J.; Purkayastha A.; Barua A.G.; Zanthoxylum alatum ameliorates scopolamine-induced amnesia in rats: Behavioral, biochemical, and molecular evidence. Indian J Pharmacol 2018,50(1),30-38","journal-title":"Indian J Pharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"608","DOI":"10.2174\/1871527317666180724150839","volume":"17","author":"Jiang X.W.","year":"2018","unstructured":"Jiang X.W.; Lu H.Y.; Xu Z.; Liu T.Y.; Wu Q.; Yang Y.; Zhao Q.C.; Gao H.Y.; In Silico analyses for key genes and molecular genetic mechanism in epilepsy and Alzheimer\u2019s disease. CNS Neurol Disord Drug Targets 2018,17(8),608-617","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/1871527317666181004155136","volume":"18","author":"Sharma S.","year":"2019","unstructured":"Sharma S.; Sarathlal K.C.; Taliyan R.; Epigenetics in neurodegenerative diseases: the role of histone deacetylases. CNS Neurol Disord Drug Targets 2019,18(1),11-18","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/oxfordjournals.bmb.a072101","volume":"42","author":"Rossor M.","year":"1986","unstructured":"Rossor M.; Iversen L.L.; Non-cholinergic neurotransmitter abnormalities in Alzheimer\u2019s disease. Br Med Bull 1986,42(1),70-74","journal-title":"Br Med Bull"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","volume":"65","author":"Aizenstein H.J.","year":"2008","unstructured":"Aizenstein H.J.; Nebes R.D.; Saxton J.A.; Price J.C.; Mathis C.A.; Tsopelas N.D.; Ziolko S.K.; James J.A.; Snitz B.E.; Houck P.R.; Bi W.; Cohen A.D.; Lopresti B.J.; DeKosky S.T.; Halligan E.M.; Klunk W.E.; Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008,65(11),1509-1517","journal-title":"Arch Neurol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nsmb.1799","volume":"17","author":"Ahmed M.","year":"2010","unstructured":"Ahmed M.; Davis J.; Aucoin D.; Sato T.; Ahuja S.; Aimoto S.; Elliott J.I.; Van Nostrand W.E.; Smith S.O.; Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol 2010,17(5),561-567","journal-title":"Nat Struct Mol Biol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"926","DOI":"10.2174\/1570159X15666170116143743","volume":"15","author":"Ricciarelli R.","year":"2017","unstructured":"Ricciarelli R.; Fedele E.; The amyloid cascade hypothesis in Alzheimer\u2019s disease: it\u2019s time to change our mind. Curr Neuropharmacol 2017,15(6),926-935","journal-title":"Curr Neuropharmacol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13195-019-0520-1","volume":"11","author":"Egan M.F.","year":"2019","unstructured":"Egan M.F.; Mukai Y.; Voss T.; Kost J.; Stone J.; Furtek C.; Mahoney E.; Cummings J.L.; Tariot P.N.; Aisen P.S.; Vellas B.; Lines C.; Michelson D.; Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer\u2019s disease. Alzheimers Res Ther 2019,11(1),68","journal-title":"Alzheimers Res Ther"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","volume":"378","author":"Egan M.F.","year":"2018","unstructured":"Egan M.F.; Kost J.; Tariot P.N.; Aisen P.S.; Cummings J.L.; Vellas B.; Sur C.; Mukai Y.; Voss T.; Furtek C.; Mahoney E.; Harper Mozley L.; Vandenberghe R.; Mo Y.; Michelson D.; Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 2018,378(18),1691-1703","journal-title":"N Engl J Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"19235","DOI":"10.1074\/jbc.R116.746032","volume":"291","author":"Andrew R.J.","year":"2016","unstructured":"Andrew R.J.; Kellett K.A.; Thinakaran G.; Hooper N.M.; A Greek tragedy: the growing complexity of Alzheimer amyloid precursor protein proteolysis. J Biol Chem 2016,291(37),19235-19244","journal-title":"J Biol Chem"},{"key":"ref=57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17091447","volume":"17","author":"More S.V.","year":"2016","unstructured":"More S.V.; Kumar H.; Cho D.Y.; Yun Y.S.; Choi D.K.; Toxin-induced experimental models of learning and memory impairment. Int J Mol Sci 2016,17(9)","journal-title":"Int J Mol Sci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00213-011-2456-4","volume":"220","author":"Lenz R.A.","year":"2012","unstructured":"Lenz R.A.; Baker J.D.; Locke C.; Rueter L.E.; Mohler E.G.; Wesnes K.; Abi-Saab W.; Saltarelli M.D.; The scopolamine model as a pharmacodynamic marker in early drug development. Psychopharmacology (Berl) 2012,220(1),97-107","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2174\/1871527317666181114163515","volume":"18","author":"Gupta S.","year":"2019","unstructured":"Gupta S.; Singhal N.K.; Ganesh S.; Sandhir R.; Extending arms of insulin resistance from diabetes to Alzheimer\u2019s disease: identification of potential therapeutic targets. CNS Neurol Disord Drug Targets 2019,18(3),172-184","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"352","DOI":"10.2174\/1871527318666190319141835","volume":"18","author":"Ali F.","year":"2019","unstructured":"Ali F.; Siddique Y.H.; Bioavailability and pharmaco-therapeutic potential of luteolin in overcoming Alzheimer\u2019s disease. CNS Neurol Disord Drug Targets 2019,18(5),352-365","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2174\/1871527318666190906101326","volume":"18","author":"Reeta","year":"2019","unstructured":"Reeta ; Baek SC; Lee JP; Ethyl acetohydroxamate incorporated\n chalcones: unveiling a novel class of chalcones for multitarget\n monoamine oxidase-B inhibitors against Alzheimer's disease. CNS Neurol Disord Drug Targets 2019,18(8),643-54","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12640-018-9901-7","volume":"34","author":"Malikowska-Racia N.","year":"2018","unstructured":"Malikowska-Racia N.; Podkowa A.; Sa\u0142at K.; Phencyclidine and scopolamine for modeling amnesia in rodents: direct comparison with the use of barnes maze test and contextual fear conditioning test in mice. Neurotox Res 2018,34(3),431-441","journal-title":"Neurotox Res"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S0893-133X(98)00067-0","volume":"20","author":"Newcomer J.W.","year":"1999","unstructured":"Newcomer J.W.; Farber N.B.; Jevtovic-Todorovic V.; Selke G.; Melson A.K.; Hershey T.; Craft S.; Olney J.W.; Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999,20(2),106-118","journal-title":"Neuropsychopharmacology"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cbi.2016.02.013","volume":"259","author":"Brimijoin S","year":"2016","unstructured":"Brimijoin S; Chen VP; Pang YP; Geng L; Gao Y; Physiological roles for butyrylcholinesterase: a BChE-ghrelin axis. Chem Biol Interact 2016,259(Pt B),271-5","journal-title":"Chem Biol Interact"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1017\/S1041610203008676","volume":"14","author":"Greig N.H.","year":"2002","unstructured":"Greig N.H.; Lahiri D.K.; Sambamurti K.; Butyrylcholinesterase: an important new target in Alzheimer\u2019s disease therapy. Int Psychogeriatr 2002,14(Suppl. 1),77-91","journal-title":"Int Psychogeriatr"},{"key":"ref=66","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22030410","volume":"22","author":"Lian W.","year":"2017","unstructured":"Lian W.; Fang J.; Xu L.; Zhou W.; Kang D.; Xiong W.; Jia H.; Liu A.L.; Du G.H.; DL0410 ameliorates memory and cognitive impairments induced by scopolamine via increasing cholinergic neurotransmission in mice. Molecules 2017,22(3)","journal-title":"Molecules"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/179355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T07:31:19Z","timestamp":1597390279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/179355\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527319666200214104331","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}